The massive EPS miss is largely non-cash and non-recurring, but the 22% revenue decline and 38% AlterG drop signal real operational headwinds from working capital constraints. The delayed 10-Q filing adds uncertainty. Watch for the Q2/Q3 shipment catch-up on secured AlterG orders and the ORMD-0801 Phase 2 trial start as potential catalysts. The $11.4M cash position provides a runway, but the company is burning ~$3.7M/quarter in operations.
Price Chart
Executive Summary
Lifeward reported Q1 2026 revenue of $3.9M (down 22% YoY) and a GAAP net loss of $10.8M ($6.70/share), massively missing the single-analyst consensus EPS estimate of -$0.34. The headline miss is driven by a one-time $4.9M non-cash acquired in-process R&D charge from the Oratech acquisition, but core operations also weakened: AlterG revenue fell 38% due to working capital constraints, gross margin contracted to 34.2% from 42.2%, and the GAAP operating loss more than doubled to $10.3M. The company delayed its 10-Q filing, adding uncertainty.
Key Financial Metrics
Key Facts
- Revenue fell 22% YoY to $3.9M, missing the $5.8M consensus
- GAAP EPS of -$6.70 vs consensus -$0.34 — a 958.8% miss driven by a $4.9M non-cash IPR&D charge from the Oratech acquisition
- Non-GAAP adjusted net loss was $5.1M ($3.13/share), compared to $4.6M ($5.28/share) in Q1 2025
- AlterG revenue declined 38% to $2.1M due to working capital constraints affecting sourcing and supply chain
- Gross margin contracted to 34.2% from 42.2% YoY, driven by lower production volumes, tariffs, and FX
- Cash used in operations improved to $3.7M from $5.5M YoY; cash balance rose to $11.4M from $2.2M at year-end 2025, boosted by $10M financing and $6.5M cash from Oratech acquisition
- Company delayed filing of its Q1 2026 10-Q, citing need for additional time to finalize accounting related to the strategic transaction
- ReWalk personal exoskeleton sales increased 11% to $1.6M; MyoCycle FES bike sales flat at $0.2M
- Weighted average shares outstanding nearly doubled to 1.6M from 0.87M YoY, reflecting the reverse split and equity issuance
Financial Impact
Revenue miss of ~$1.9M (33% below consensus); GAAP EPS miss of $6.36 vs consensus; operating loss doubled to $10.3M; gross margin down 800 bps
Risk Factors
- Delayed 10-Q filing may trigger Nasdaq listing compliance concerns or covenant issues
- Working capital constraints continue to impair AlterG supply chain and revenue
- Integration of Oratech and execution on the oral insulin pipeline are unproven
- Dilution from the convertible notes and warrant liabilities ($6.8M) could pressure the stock
- Revenue concentration in AlterG (54% of total) leaves the company exposed to further supply chain disruptions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $7.45 $7.11 | ▼ −4.56% | ▼ −2.57% | $5.85 (−21.48%) |
Aug 14, 2026 7w ago | Press Release | $7.45 $7.11 | ▲ +4.56% | ▲ +2.57% | $5.85 (+21.48%) |
Aug 11, 2026 7w ago | EFFECT | $7.57 $7.40 | ▲ +2.18% | ▲ +1.12% | $5.85 (+22.67%) |
Aug 7, 2026 8w ago | Press Release | $7.69 $6.98 | ▼ −9.17% | ▼ −8.78% | $5.85 (−23.88%) |
May 19, 2026 19w ago | 8-K | $6.40 $6.98 | ▲ +9.06% | ▲ +8.08% | $5.85 (−8.59%) |
May 15, 2026 20w ago | 8-K | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 15, 2026 20w ago | Press Release | $6.70 $6.96 | ▼ −3.81% | ▼ −1.69% | $5.85 (+12.69%) |
May 13, 2026 20w ago | EFFECT | $6.63 $6.80 | ▼ −2.56% | ▼ −3.18% | $5.85 (+11.76%) |
May 11, 2026 20w ago | Press Release | $6.40 $6.98 | ▲ +9.09% | ▲ +9.40% | $5.85 (−8.59%) |
Apr 27, 2026 22w ago | S-3 | $7.09 $6.98 | ▲ +1.55% | ▲ +7.02% | $5.85 (+17.49%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access